FRET-based detection of M1 muscarinic acetylcholine receptor activation by orthosteric and allosteric agonists

Muscarinic acetylcholine receptors (mAChRs) are 7-transmembrane, G protein-coupled receptors that regulate a variety of physiological processes and represent potentially important targets for therapeutic intervention. mAChRs can be stimulated by full and partial orthosteric and allosteric agonists,...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 7; no. 1; p. e29946
Main Authors Markovic, Danijela, Holdich, Jonathan, Al-Sabah, Suleiman, Mistry, Rajendra, Krasel, Cornelius, Mahaut-Smith, Martyn P, Challiss, R A John
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 2012
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Muscarinic acetylcholine receptors (mAChRs) are 7-transmembrane, G protein-coupled receptors that regulate a variety of physiological processes and represent potentially important targets for therapeutic intervention. mAChRs can be stimulated by full and partial orthosteric and allosteric agonists, however the relative abilities of such ligands to induce conformational changes in the receptor remain unclear. To gain further insight into the actions of mAChR agonists, we have developed a fluorescently tagged M(1) mAChR that reports ligand-induced conformational changes in real-time by changes in Förster resonance energy transfer (FRET). Variants of CFP and YFP were inserted into the third intracellular loop and at the end of the C-terminus of the mouse M(1) mAChR, respectively. The optimized FRET receptor construct (M(1)-cam5) was expressed stably in HEK293 cells. The variant CFP/YFP-receptor chimera expressed predominantly at the plasma membrane of HEK293 cells and displayed ligand-binding affinities comparable with those of the wild-type receptor. It also retained an ability to interact with Gα(q/11) proteins and to stimulate phosphoinositide turnover, ERK1/2 phosphorylation and undergo agonist-dependent internalization. Addition of the full agonist methacholine caused a reversible decrease in M(1) FRET (F(EYFP)/F(ECFP)) that was prevented by atropine pre-addition and showed concentration-dependent amplitude and kinetics. Partial orthosteric agonists, arecoline and pilocarpine, as well as allosteric agonists, AC-42 and 77-LH-28-1, also caused atropine-sensitive decreases in the FRET signal, which were smaller in amplitude and significantly slower in onset compared to those evoked by methacholine. The M(1) FRET-based receptor chimera reports that allosteric and orthosteric agonists induce similar conformational changes in the third intracellular loop and/or C-terminus, and should prove to be a valuable molecular reagent for pharmacological and structural investigations of M(1) mAChR activation.
Bibliography:Current address: Institut für Pharmakologie & Toxikologie, Marburg, Germany
Current address: Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
Current address: Department of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, Safat, Kuwait
Current address: Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom
Conceived and designed the experiments: DM MPM-S RAJC. Performed the experiments: DM JPH SA-S RM CK. Analyzed the data: DM JPH SA-S RM CK MPM-S RAJC. Wrote the paper: DM MPM-S RAJC.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0029946